drugset / Trial / NCT05309460

Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial

NCT05309460

Phase 4 Recruiting 600 enrolled Nebraska Methodist Health System
RandomizedParallel-groupOpen-labelTreatment

Summary

Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.

Timeline

Start
2022-06-20
Primary completion
2024-05-01
Completion
2024-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Labetalol Small molecule 200 mg Oral
Comparator Nifedipine Other / unclassified 30 mg

Indications